AstraZeneca and Bristol Myers Squibb reportedly in merger talks for potential $400 billion pharmaceutical giant

UK drugmaker AstraZeneca is reportedly exploring a potential megadeal to combine with U.S. rival Bristol Myers Squibb, which could create one of the world's largest pharmaceutical groups with a combined value of nearly $400 billion. Discussions have been ongoing in recent months, with a deal potentially materializing soon, though it could also be delayed or fall apart.